📅 PUBMED DAILY TRIAGE — 2026-03-24
Window: 2026-03-23T00:00:00Z → 2026-03-24T23:59:59Z (CRDT, 48h expansion) Topics scanned: 10 | Articles reviewed: 14 High priority: 3 | Standard: 9 | Low/archive: 2 | Unsolicited finds: 1 Run status: SUCCESS
🔴🟠 HIGH PRIORITY
| ID | Title | Score | Why it matters |
|---|---|---|---|
| TR-2026-03-24-001 · PMID 41871988 | In Vivo Spatiotemporal Protection and Recognition of Circulating Tumor DNA for Early Cancer Diagnosis and Monitoring | 7/10 🔴 | Novel in vivo ctDNA protection strategy (56x bioavailability boost) enables tumor detection at 30mm³ — preclinical breakthrough with direct early detection pipeline relevance. Promoted to HIGH via EARLY_CANCER_DETECTION flag. |
| TR-2026-03-24-002 · PMID 41871894 | Early prediction of adult lymphoma-associated haemophagocytic lymphohistiocytosis using an interpretable machine learning model | 8/10 🟢 | Validated random forest model (AUC 0.794) using routine CBC/lab variables distinguishes high-mortality LA-HLH from other HLH; deployed as web clinical tool — near-term implementable. |
| TR-2026-03-24-003 · PMID 41871940 | Homologous Recombination Deficiency and Genomic Alterations in Advanced Prostate Cancer: Insights for Precision Therapy | 8/10 🟠 | CGP of n=22,061 advanced prostate cancers identifies BRCA2-loss as the HRDsig-high PARPi-sensitive subset — directly refines precision therapy selection in a common cancer. |
🟢⚪ STANDARD
| ID | Title | Score | Primary Category |
|---|---|---|---|
| TR-2026-03-24-005 · PMID 41871876 | Limited expression of B-cell maturation antigen in acute myeloid leukemia | 7/10 🟠 | Treatment Innovation — refutes BCMA as CAR-T target in AML (false-positive antibody artifact); prevents misdirected clinical development. |
| TR-2026-03-24-006 · PMID 41871870 | Combined variations in sleep, physical activity, and nutrition and the risk of major adverse cardiovascular events | 7/10 🟢 | Prevention — UK Biobank n=53,242; 57% lower MACE with optimal SPAN; minimal behavior change (11 min sleep + 4.5 min activity/day) = 10% lower MACE. |
| TR-2026-03-24-004 · PMID 41871959 | Fundamentals of big data and artificial intelligence in transfusion medicine | 5/10 ⚪ | Diagnostics — Comprehensive review; AI/FHIR/precision RBC diagnostics roadmap for blood establishments. |
| TR-2026-03-24-007 · PMID 41871939 | SGLT2 inhibitors but not other antidiabetic drugs improve frailty in older adults with diabetes and HFpEF | 6/10 🟢 | Treatment Innovation — SGLT2i unique frailty benefit in elderly diabetic HFpEF patients; near-term implementable for aging/cardiometabolic population. |
| TR-2026-03-24-008 · PMID 41871801 | Functional Nanoplatforms Overcoming Immune Resistance in Skin Cancers | 5/10 ⚪ | Treatment Innovation — Review of nanoplatform immunotherapy for melanoma/SCC/MCC; AI-driven design + liquid biopsy integration discussed. |
| TR-2026-03-24-009 · PMID 41871727 | Mitochondria in sarcoma and carcinoma: Achilles' heel or Hercules' strength? | 4/10 ⚪ | Drug Development — Review; sarcoma mitochondrial targeting highlighted as uniquely promising due to high mitochondrial content. |
| TR-2026-03-24-010 · PMID 41872011 | Patient-derived organoids in renal cell carcinoma: A review of methodologies and applications | 4/10 ⚪ | Drug Development — PDO platforms for RCC drug screening/precision oncology; translational challenges noted. |
| TR-2026-03-24-011 · PMID 41871887 | Effects of Nutritional Supplement Intake on Pregnancy Outcomes in Overweight and Obese Women | 6/10 🟢 | Prevention — Meta-analysis (19 RCTs, n=3,482); inositol/omega-3 beneficial, probiotics increase preterm birth risk (RR 1.86) in obese pregnant women. |
| TR-2026-03-24-014 · PMID 41871725 | Precision Oncology Meets Nanotechnology: AI-Driven Liposomal Nanocarriers for Enhanced Cancer Immunotherapy | 4/10 ⚪ | Treatment Innovation — Review of AI-engineered liposomal nanocarriers for immunotherapy/chemoimmunotherapy. |
💡 UNSOLICITED FINDS
| ID | Title | Signal |
|---|---|---|
| TR-2026-03-24-013 · PMID 41872059 | SIECHI: A systems model of elite capture and structural inertia in health inequity | Score 2/10 — Conceptual public health editorial; low relevance to core biomedical watchlist. Not pipeline-ready. |
📊 TODAY'S BREAKDOWN
By research category:
- Treatment Innovation: 5
- Prevention: 3
- Diagnostics: 3
- Drug Development: 3
- Early Detection: 1
- Genomics/Precision Medicine: 1 (also counted in Treatment Innovation)
- Public Health: 2
By evidence maturity:
- Exploratory: 7
- Validated: 7
- Potentially Practice-Changing: 0
By watchlist topic (articles):
- Hematologic malignancies: 3 (PMID 41871876, 41871894, 41872079)
- AI/ML in diagnostics: 4 (PMID 41871894, 41871959, 41871801, 41871725)
- Early cancer detection (ctDNA/liquid biopsy): 2 (PMID 41871988, 41871727)
- Novel therapeutics (immunotherapy/targeted): 4 (PMID 41871876, 41871801, 41871940, 41871725)
- Cardiovascular-metabolic: 3 (PMID 41871870, 41871887, 41871939)
- Precision oncology/genomics: 3 (PMID 41871940, 41871727, 41871725)
- Aging/longevity/population health: 2 (PMID 41871870, 41871939)
- CBC/hematology ML: 1 (PMID 41871894)
- Rare diseases: 1 (PMID 41872079 — PTCL case report)
By source type:
- Peer-reviewed: 14 | Preprint: 0
🔧 RUN NOTES
- Window expansion triggered: Zero results on CRDT 2026-03-24 alone at 09:00 UTC. Expanded to 48h window (2026-03-23:2026-03-24) per protocol for all 9 watchlist topics + sentinel scan.
- Deduplication applied: PMID 41869312 suppressed (previously emitted 2026-03-23 run). Total 12 prior fingerprints checked.
- Daily cap not hit for any topic except sentinel (699 raw results capped at 10 per protocol).
- Access level: All records abstract-only; no PMC full text reviewed this run.
- Alert suppression: PMID 41872087 (Ofuji syndrome/Hodgkin lymphoma case report) excluded from records — single case report with no abstract.
- Overlap note: 48h window may include records indexed on 2026-03-23 already surfaced in prior run. Fingerprint deduplication applied; no additional overlapping PMIDs detected beyond 41869312.
- 3 HIGH priority articles → Telegram alerts emitted (max 5 cap, 3 in this run).